20.648 articles found

A double-blind, controlled trial of circadian effective light therapy in patients with Parkinson's disease.

Wyman BT, Adams D, Hendrix S, Groves J, Croft W, Ellison N, Olanow CW, Kieburtz K.

Neurotherapeutics · 2025-09-02

DOI: 10.1016/j.neurot.2025.e00728PMID: 40903343

Add-on therapies to levodopa improve pain modulation in Parkinson's disease with motor fluctuations: A prospective cohort study.

Andrenelli E, Baldini N, Barbini FA, Benedetti M, Brambatti J, Capecci M, Ceravolo MG.

Parkinsonism Relat Disord · 2025-09-02

DOI: 10.1016/j.parkreldis.2025.108019PMID: 40939528

Effects of Levodopa on Gait in People With Parkinson's Disease With and Without a History of Falls.

Shah VV, Carlson-Kuhta P, Nutt JG, Horak FB, Mancini M.

Mov Disord Clin Pract · 2025-09-02

DOI: 10.1002/mdc3.70330PMID: 40891191

Clinical insights into catechin-based nanomedicine: a review of therapeutic potential in neurodegenerative diseases

Al Amin M, Zehravi M, Sweilam SH, Shanmugarajan TS, Arjun UVNV, Nagaiyan MB, Reddy SM, Subash V, swarnalatha KM, Pazhanikumar A, Mart J, Prasad PD, Khan MI, Ahmad I, Emran TB.

3 Biotech · 2025-09-01

Anti-neurodegenerative treatment in Alzheimer's disease: Multifaceted mechanisms of action of berberine.

Song D, Zhang C.

Int J Clin Pharmacol Ther · 2025-09-01

DOI: 10.5414/cp204725PMID: 40454536

Behavioral Compared With Drug Therapy for Overactive Bladder Symptoms in Parkinson Disease: A Randomized Noninferiority Trial.

Vaughan CP, Morley JF, Lehosit J, McGwin G, Muirhead L, Khakharia A, Johnson TM, Evatt ML, Sergent T, Burgio KL, Markland AD.

JAMA Neurol · 2025-09-01

DOI: 10.1001/jamaneurol.2025.1904PMID: 40658410

Late-Onset Oral Cenesthopathy With Dopaminergic Dysfunction: Therapeutic Response to Pramipexole in a Case With Suspected Prodromal Lewy Body Disease.

Matsui H, Tamura T, Kameyama M, Omori Y, Sugihara G, Takeuchi T, Takahashi H, Furuta K.

Psychogeriatrics · 2025-09-01

DOI: 10.1111/psyg.70088PMID: 40859748

Multimodal Imaging of Blood-Brain Barrier Dysfunction in Parkinson's Disease: From Pathological Mechanisms to Therapeutic Opportunities.

Lu Z, Yin H, Xiang P, Yi X, Tian X, Gong Q.

Eur J Neurosci · 2025-09-01

DOI: 10.1111/ejn.70237PMID: 40888202

Advances in Neurodegenerative Disease Therapy: Stem Cell Clinical Trials and Promise of Engineered Exosomes.

Isik S, Osman S, Yeman-Kiyak B, Shamshir SRM, Sanchez NME.

CNS Neurosci Ther · 2025-09-01

DOI: 10.1111/cns.70577PMID: 40904199

Identifying Poor Responders to STN DBS in Parkinson Disease: The Role of Rapid Disease Progression in the First Year in Optimal Responders to Levodopa.

Morgante F, Artusi CA, Ricciardi L, Sarchioto M, Montanaro E, Edwards MJ, Lopiano L, Zibetti M.

Eur J Neurol · 2025-09-01

DOI: 10.1111/ene.70342PMID: 40919786

Neurotransmitter Transporters-Unraveling Molecular Mechanisms and Therapeutic Opportunities.

Sitte HH, Gether U, Cabrita E, Stockner T.

J Neurochem · 2025-09-01

DOI: 10.1111/jnc.70240PMID: 40984722

Efficacy of low-frequency repetitive transcranial magnetic stimulation in the treatment of sleep disorders in the early stage of Parkinson disease: A single-center double-blind controlled study.

Feng Z, Li M, Zheng Y, Ping W, Zhou Z.

Medicine (Baltimore) · 2025-09-01

DOI: 10.1097/md.0000000000044780PMID: 40988161